Literature DB >> 2379765

Glycation of very low density lipoprotein from rat plasma impairs its catabolism.

J C Mamo1, L Szeto, G Steiner.   

Abstract

Rat VLDL were glycated in vitro in the presence or absence of a reducing agent. Prior to glycation, the VLDL triglyceride was endogenously radiolabelled with [3H]-oleic acid. Post glycation the VLDL B-apoprotein was exogenously radiolabelled with [131]I. The double labelled VLDL was then injected into normal rats and the decline in plasma radioactivity of the two isotopes was used as a measure of triglyceride and particle clearance. VLDL glycated in either the presence or absence of reducing agent exhibited a significantly slower removal of triglyceride and apoprotein B compared to normal VLDL. The ability of glycated VLDL triglyceride to act as substrate for lipoprotein lipase and hepatic lipase was examined. Increasing concentrations of normal and glycated VLDL triglyceride were incubated with post-heparin plasma. The kinetics of triglyceride hydrolysis were determined in a manner analogous to Michaelis-Menten analysis. Glycated VLDL was found to be poorer than normal VLDL as a substrate for lipoprotein lipase. Glycation of VLDL appears to interfere with the lipolysis of its triglyceride. This may explain the delayed clearance of glycated VLDL triglyceride in vivo. Glycation also extended the mean plasma residence time of the VLDL particle. These factors may, in part, contribute to the hypertriglyceridaemia observed in subjects with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379765     DOI: 10.1007/bf00404637

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  Studies on the radioiodination of very low density lipoprotein obtained from different mammalian species.

Authors:  N H Fidge; P Poulis
Journal:  Clin Chim Acta       Date:  1974-03       Impact factor: 3.786

2.  Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

Authors:  M J Garcia; P M McNamara; T Gordon; W B Kannel
Journal:  Diabetes       Date:  1974-02       Impact factor: 9.461

3.  Fractionation of the C-apoproteins from human plasma very low density lipoproteins.

Authors:  P N Herbert; R S Shulman; R I Levy; D S Fredrickson
Journal:  J Biol Chem       Date:  1973-07-25       Impact factor: 5.157

4.  The independent synthesis of intermediate density lipoproteins in type III hyperlipoproteinemia.

Authors:  M F Reardon; M E Poapst; G Steiner
Journal:  Metabolism       Date:  1982-05       Impact factor: 8.694

5.  Sites of nonenzymatic glycosylation of human hemoglobin A.

Authors:  R Shapiro; M J McManus; C Zalut; H F Bunn
Journal:  J Biol Chem       Date:  1980-04-10       Impact factor: 5.157

6.  Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism.

Authors:  U P Steinbrecher; J L Witztum
Journal:  Diabetes       Date:  1984-02       Impact factor: 9.461

7.  A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins.

Authors:  L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

8.  Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity.

Authors:  J L Witztum; E M Mahoney; M J Branks; M Fisher; R Elam; D Steinberg
Journal:  Diabetes       Date:  1982-04       Impact factor: 9.461

9.  The chromogenicity and quantitation of apoB-100 and apoB-48 of human plasma lipoproteins on analytical SDS gel electrophoresis.

Authors:  M Poapst; K Uffelman; G Steiner
Journal:  Atherosclerosis       Date:  1987-05       Impact factor: 5.162

10.  Metabolism of homologous and heterologous lipoproteins by cultured rat and human skin fibroblasts.

Authors:  C A Drevon; A D Attie; S H Pangburn; D Steinberg
Journal:  J Lipid Res       Date:  1981-01       Impact factor: 5.922

View more
  4 in total

1.  Heparin binding triggers human VLDL remodeling by circulating lipoprotein lipase: Relevance to VLDL functionality in health and disease.

Authors:  Shobini Jayaraman; Antonio Pérez; Inka Miñambres; Jose Luis Sánchez-Quesada; Olga Gursky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-10-02       Impact factor: 4.698

2.  Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy.

Authors:  J F Poduslo; G L Curran
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

Review 3.  Pathophysiology of diabetic dyslipidaemia: where are we?

Authors:  Bruno Vergès
Journal:  Diabetologia       Date:  2015-03-01       Impact factor: 10.122

Review 4.  Dyslipidemia in Pediatric Type 2 Diabetes Mellitus.

Authors:  Bhuvana Sunil; Ambika P Ashraf
Journal:  Curr Diab Rep       Date:  2020-09-09       Impact factor: 4.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.